Top

Published in:

01-10-2014 | Short Communication

Prevalence and predictors of blood-brain barrier damage in the HAART era

Authors: A. Calcagno, M. C. Alberione, A. Romito, D. Imperiale, V. Ghisetti, S. Audagnotto, F. Lipani, S. Raviolo, G. Di Perri, S. Bonora

Published in: Journal of NeuroVirology | Issue 5/2014

Abstract

Blood-brain barrier damage (BBBD) is prevalent in HIV-positive patients and may enhance cell trafficking to the central nervous system. A retrospective analysis in adult HIV-positive patients with no central nervous system disease was conducted in order to estimate the prevalence and risk factors of BBBD (according to cerebrospinal fluid to plasma albumin ratios). One hundred fifty-eight HIV-positive adult patients were included. BBBD impairment and intrathecal IgG synthesis were respectively observed in 45 (28.5 %) and 100 patients (63.3 %). Low CD4 nadir and high CSF HIV RNA were independently associated with both abnormalities. BBBD is common in HIV-positive patients, and its main determinants are advanced immune depression and compartmental viral replication.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M (2002) Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 16:2145–2149CrossRefPubMed

Abdulle S, Hagberg L, Gisslèn M (2005) Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med 6:164–169CrossRefPubMed

Andersson LM, Hagbwerg L, Fuchs D, Svennerholm B, Gisslen M (2001) Increased blood brain-barrier permeability in neuroasymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 7:542–547CrossRefPubMed

Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C (1993) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 33:129–133CrossRefPubMed

Calcagno A, Bonora S, Simiele M et al (2011) Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brain barrier damage. AIDS 25(11):1437–9CrossRefPubMed

Calcagno A, Cusato J, Simiele M et al (2014) High interpatient variability of raltegravir cerebrospinal fluid concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother 69(1):241–5CrossRefPubMed

Caroscio JT, Kochwa S, Sacks H, Makuku S, Cohen JA, Yahr MD (1986) Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis. Arch Neurol 43(11):1129–31CrossRefPubMed

Chalbot S, Zetterberg H, Blennow K et al (2011) Blood-cerebrospinal fluid barrier permeability in Alzheimer’s disease. J Alzheimers Dis 25(3):505–15PubMedCentralPubMed

Comabella M, Montalban X (2014) Body fluid biomarkers in multiple sclerosis. Lancet Neurol 13(1):113–26CrossRefPubMed

Ellis et al (2011) For the CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747–1751CrossRefPubMed

Elovaara I, Iivanainen M, Valle SL, Suni J, Tervo T, Lähdevirta J (1987) CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations. J Neurol Sci 78(3):331–342

Hall CD, Snyder CR, Robertson KR, Messenheimer JA, Wilkins JW, Robertson WT, Whaley RA, Van der Horst C, Silverman LM (1992) Cerebrospinal fluid analysis in human immunodeficiency virus infection. Ann Clin Lab Sci 22(3):139–43PubMed

Ivey NS, Mac Lean AG, Lackner AA (2009) AIDS and the blood brain barrier. J Neurovirol 15(2):111–122CrossRefPubMedCentralPubMed

Kamat A, Lyons JL, Misra V et al (2012) Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 60(3):234–43CrossRefPubMedCentralPubMed

Lefvert AK, Link H (1985) IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol 17(1):13–20CrossRefPubMed

Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell RN (1988) Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 45:954–958CrossRefPubMed

Marshall DW, Brey RL, Butzin CA et al (1991) CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J Acquir Immune Defic Syndr 4(8):777–81PubMed

Mocroft A, Lundgren JD, Sabin ML et al (2013) Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study. PLoS Med 10(9):e1001510CrossRefPubMedCentralPubMed

Nakashima I, Fujihara K, Itoyama Y (1999) Oligoclonal IgG bands in Japanese multiple sclerosis patients. J Neuroimmunol 101(2):205–6CrossRefPubMed

Petito CK, Cash KS (1992) Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 32:658–666CrossRefPubMed

Reiber H (1995) External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 41(2):256–63PubMed

Strazza M, Pirrone V, Wigdahl B (2011) Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 1399:96–115CrossRefPubMedCentralPubMed

Tourtellotte WW, Ma BI (1978) Multiple sclerosis: the blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28(9 Pt 2):76–83CrossRefPubMed

Yilmaz A, Gisslén M, Spudich S et al (2009) Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4(9):e6877CrossRefPubMedCentralPubMed

Yilmaz A, Yiannoutsos CT, Fuchs D et al (2013) Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 10:62CrossRefPubMedCentralPubMed

Zetterberg H, Jakobsson J, Redsäter M et al (2014) Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. doi:10.1016/j.psychres.2014.03.045 PubMed

Title: Prevalence and predictors of blood-brain barrier damage in the HAART era
Authors: A. Calcagno
M. C. Alberione
A. Romito
D. Imperiale
V. Ghisetti
S. Audagnotto
F. Lipani
S. Raviolo
G. Di Perri
S. Bonora
Publication date: 01-10-2014
Publisher: Springer US
Published in: Journal of NeuroVirology / Issue 5/2014
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-014-0266-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevalence and predictors of blood-brain barrier damage in the HAART era

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

CNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. Case report and literature review

Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry

Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood

Impact of human immunodeficiency virus on neurocognition and risky behaviors in young adults

Infected peripheral blood mononuclear cells transmit latent varicella zoster virus infection to the guinea pig enteric nervous system

Robust pro-inflammatory and lesser anti-inflammatory immune responses during primary simian varicella virus infection and reactivation in rhesus macaques